biotech

biotech Articles

Biotechnology company Replimune intends to price more than 6 million shares in an initial public offering valued up to more than $123 million.
Acceleron Pharma and Celgene each saw a handy gain on Tuesday morning after it was announced results from their late-stage study in adults with transfusion-dependent beta-thalassemia.
Axovant Sciences shares saw a handy gain on Monday after the company announced that it has licensed exclusive global rights to an investigational gene therapy program from Benitec Biopharma.
Constellation Pharmaceuticals intends to price more than 5 million shares to result in an initial public offering valued up to more than $98 million.
KemPharm shares dipped on Monday after the firm announced topline results from its ADHD clinical trial.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in July.
Biogen shares jumped early on Friday after the firm, in conjunction with Eisai, announced positive results from a midstage Alzheimer’s study.
Zynerba Pharmaceuticals shares were crushed early on Thursday after the company reported topline results from an early stage clinical study.
Clovis Oncology shares saw a bump early on Thursday after the company announced that the European Medicines Agency has validated its application for a Type 2 variation to the marketing authorization...
Juniper Pharmaceuticals shares jumped early on Tuesday after the company announced that it would be acquired by Catalent.
Nuvectra shares were crushed on Monday after the company announced an update on its FDA premarket approval application and its TÜV SÜD application for CE Mark in Europe for Virtis.
Adamis Pharmaceuticals saw its shares shoot up early on Monday after the firm announced a partnership with a subsidiary of Novartis.
Here are a few biotech and pharmaceutical companies to watch for in the coming week and for the month of July.
A few biopharma stocks made massive runs over the course of this past week, some losing more than half their cap. Not all these moves were negative, but the overall sentiment was negative.
Acceleron Pharma and Celgene each saw gains on Friday after they reported results from a late-stage trial.